Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2017 02:15 ET | Source: Novartis Pharma AG

Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA

Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a...
October 30, 2017 02:00 ET | Source: Novartis Pharma AG

Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio

Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera®, a first-in-class RadioLigand Therapy (RLT)...
October 28, 2017 02:55 ET | Source: Novartis Pharma AG

Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease modifying...
October 27, 2017 01:15 ET | Source: Novartis Pharma AG

Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review

Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of...
October 25, 2017 11:30 ET | Source: Novartis Pharma AG

Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS

Full data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time With 54 accepted abstracts, Novartis presence spans from new...
October 24, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis steigert im dritten Quartal Umsatz und Gewinn in allen Divisionen

Der Nettoumsatz steigt mit einem Wachstum in allen Divisionen um 2% (kWk[1], +2% USD): Cosentyx (USD 556 Millionen, +83% kWk) wächst in allen Indikationen stark Entresto (USD 128 Millionen,...
October 24, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis: au troisième trimestre, croissance du chiffre d'affaires et du résultat dans toutes les divisions

Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses...
October 24, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis delivered growth on top and bottom line in all divisions in Q3

Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew...
October 23, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients

Breakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo1 ...
October 18, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)

Nearly 70% of patients maintained platelet counts of >=30×109/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently...